Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 7682 results

  1. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  2. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Botulinum toxin type A for preventing episodic migraine ID 6450

    Awaiting development [GID-TA11505] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437

    Awaiting development [GID-TA11563] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448

    Awaiting development [GID-TA11564] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development [GID-TA11560] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    Awaiting development [GID-TA11516] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development